{"id":60337,"date":"2024-11-14T10:04:21","date_gmt":"2024-11-14T09:04:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/"},"modified":"2024-11-14T10:04:21","modified_gmt":"2024-11-14T09:04:21","slug":"greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/","title":{"rendered":"Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer"},"content":{"rendered":"
\n

OXFORD, England–(BUSINESS WIRE)–Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer. An accomplished biotech and healthcare executive, Ms. Deptula-Hicks most recently served as Chief Financial Officer of F-star Therapeutics Inc. (FSTX), which she took public on the NASDAQ in 2020, through to the successful sale of the company in 2023.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cI\u2019m delighted to officially welcome Darlene as our Chief Financial Officer and I am excited about the impact she will bring to Greywolf as we progress our first-in-class antigen modulators through the clinic,\u201d said Peter Joyce, CEO & Co-founder of Greywolf Therapeutics. \u201cDarlene\u2019s extensive biotech financing and US public company experience will be instrumental in helping us to achieve our growth ambitions and strengthen our ability to deliver our first-in-class treatments to patients.\u201d<\/p>\n

\nMs. Deptula-Hicks brings over 30 years of corporate finance, capital markets, M&A, accounting and investor relations experience within publicly listed US companies and private healthcare and biotech companies. Recently and prior to F-Star, she worked in CFO roles across numerous biotech and pharmaceutical companies, including Normunity, Northern Biologics, Pieris Pharmaceuticals (PIRS) and T2 Biosystems, (TTOO) and has a longstanding track record of growing companies and raising capital in public and private equity markets. She also currently serves on the boards of Abcuro and Avacta Therapeutics.<\/p>\n

\n\u201cI am thrilled to be joining Greywolf at this exciting time and see great potential in its novel antigen modulation technology to address the growing need for more efficacious therapies for patients.\u201d said Ms. Deptula-Hicks, \u201cIt\u2019s exciting to be part of an energized, growing organization and I am looking forward to working alongside Peter and the team to build on our recent financial and operational success.\u201d<\/p>\n

\nAbout Greywolf Therapeutics<\/b><\/p>\n

\nGreywolf Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology which controls T cells to guide the immune system. Greywolf’s technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system and the company is progressing first-in-class antigen modulators to treat people living with autoimmune disorders, cancer and infectious diseases.<\/p>\n

\nThe company’s lead antigen modulator (GWRD5769) delivered strong results during a phase I\/II trial in oncology, demonstrating proof-of-mechanism and target engagement, while the company’s second (GRWD0715) is accelerating through preclinical development as a potential treatment within autoimmunity.<\/p>\n

\nGreywolf is headquartered in Oxford, UK.<\/p>\n

\nMore information: Website<\/a> | LinkedIn<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nGreywolf Therapeutics
\n
<\/b>Patrick White, Head of Communications
\n
+44 (0) 01235 644 970
\n
patrick.white@gwt.bio<\/a><\/p>\n

FTI Communications<\/b>
(on behalf of Greywolf)<\/b>
Ben Atwell \/ Mike Trace (media)
\n
+44 20 3727 1000
\n
GreyWolfTx@fticonsulting.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

OXFORD, England–(BUSINESS WIRE)–Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer. An accomplished biotech and healthcare executive, Ms. Deptula-Hicks most recently served as Chief Financial Officer of F-star Therapeutics Inc. (FSTX), which she took public on … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60337","6":"format-standard","7":"category-industry"},"yoast_head":"\nGreywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"OXFORD, England–(BUSINESS WIRE)–Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer. An accomplished biotech and healthcare executive, Ms. Deptula-Hicks most recently served as Chief Financial Officer of F-star Therapeutics Inc. (FSTX), which she took public on ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-14T09:04:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20241113002948\/en\/2304057\/22\/Greywolf_therapeutics_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer\",\"datePublished\":\"2024-11-14T09:04:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\\\/\"},\"wordCount\":443,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241113002948\\\/en\\\/2304057\\\/22\\\/Greywolf_therapeutics_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\\\/\",\"name\":\"Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241113002948\\\/en\\\/2304057\\\/22\\\/Greywolf_therapeutics_logo.jpg\",\"datePublished\":\"2024-11-14T09:04:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241113002948\\\/en\\\/2304057\\\/22\\\/Greywolf_therapeutics_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241113002948\\\/en\\\/2304057\\\/22\\\/Greywolf_therapeutics_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/","og_locale":"en_US","og_type":"article","og_title":"Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer - Pharma Trend","og_description":"OXFORD, England–(BUSINESS WIRE)–Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer. An accomplished biotech and healthcare executive, Ms. Deptula-Hicks most recently served as Chief Financial Officer of F-star Therapeutics Inc. (FSTX), which she took public on ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/","og_site_name":"Pharma Trend","article_published_time":"2024-11-14T09:04:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20241113002948\/en\/2304057\/22\/Greywolf_therapeutics_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer","datePublished":"2024-11-14T09:04:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/"},"wordCount":443,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241113002948\/en\/2304057\/22\/Greywolf_therapeutics_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/","url":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/","name":"Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241113002948\/en\/2304057\/22\/Greywolf_therapeutics_logo.jpg","datePublished":"2024-11-14T09:04:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20241113002948\/en\/2304057\/22\/Greywolf_therapeutics_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20241113002948\/en\/2304057\/22\/Greywolf_therapeutics_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/greywolf-appoints-darlene-deptula-hicks-as-chief-financial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60337"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60337\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}